- The fund will back biomedical technology companies
- The fund targets small- and mid-sized private companies at various stages of growth
- Catalio manages more than $1 billion in assets across its private equity, private credit, and public equities strategies
Catalio Capital Management has closed its inaugural special situations fund at over $85 million.
Catalio Credit Opportunities Fund I’s limited partners include family offices, endowments, foundations and insurance companies. The fund will back biomedical technology companies.
The fund targets small- and mid-sized private companies at various stages of growth.
“In this challenging market, we are seeing significant demand from biotech companies for structured capital financing solutions to reach the next step in their evolution,” said George Petrocheilos and Dr. Jacob Vogelstein, co-founders and managing partners of Catalio, in a statement. “We believe that this strategy provides exciting biotech companies the necessary capital and flexibility to scale their platforms.”
Catalio manages more than $1 billion in assets across its private equity, private credit, and public equities strategies. The fund is the second investment vehicle that Catalio has raised in 2022, following the close of Catalio Nexus Fund III, the firm’s third flagship private equity fund, earlier this year.
Catalio Capital Management focuses on breakthrough biomedical technology companies developing the next generation of drugs, devices, diagnostics and data-driven insights. Catalio has offices in New York, Baltimore, and London.